Met Kinase Inhibitor VI, SGX523

A cell-permeable triazolopyridazine compound that acts as a potent, ATP-competitive (K_i = 2.7 & 23 nM using non-phosphorylated and phosphorylated MET kinase domain, respectively), and highly selective inhibitor against the tyrosine kinase activity of the HGF (hepatocyte growth factor) receptor c-MET (IC₅₀ = 4 nM), while exhibiting little or no activity toward a panel of more than 210 other kinases, including the closely related RTK RON. Shown to inhibit the constitutive (IC₅₀ = 40 nM in GTL16 cells) as well as HGF-stimulated (IC₅₀ = 12 nM in A549 cells) MET autophosphorylation/activation in cultures in vitro and effectively suppress MET-dependent tumor growths in mice in vivo (twice daily oral dosings at 30 mg/kg). X-ray crystallography reveals that SGX523 locks MET in a "DFG-in" conformation with the triazolopyridazine moiety interacting with the hydrophobic side chains of Met¹²²⁹ and Tyr¹²⁴⁸, while Tyr¹²⁴⁸ mutations are found to render MET insensitive to SGX523 inhibition both in cell-free and cell-based assays.

Packaged under inert gas

Toxicity: Regulatory Review (Z)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months -20°C.

Buchanan, S.G., et al. 2009. Mol. Cancer Ther.8, 3181.
Eder, J.P., et al. 2009. Clin. Cancer Res.15, 2207.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany